Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MCK
BuyFLAGMcKesson Corporation · Healthcare · United States · $104.2B · Avg Vol: $866M/d
McKesson has quality Q68 and momentum M61 with a buyback on file, but value sits exactly at V50 and misses the all-three-above-60 path. Insiders sold 0.03% with no offsetting purchase, net selling, which is separately adverse.
COMPANY DESCRIPTION
McKesson Corporation is a global leader in healthcare services, primarily operating as a major distributor of pharmaceuticals and medical supplies, alongside providing healthcare information technology solutions and pharmacy management services. The company's immense scale, sophisticated logistics network, and deep integration within the healthcare supply chain provide a substantial competitive moat, making it an indispensable partner for pharmaceutical manufacturers and healthcare providers. McKesson plays a critical role in delivering essential medicines and medical products efficiently across the globe.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 264.0B | 276.7B | 309.0B | 359.1B | 403.4B | 11.2% | 411.0B | 431.9B | 462.3B | 7.0% |
| EPS | 7.32 | 25.23 | 22.54 | 25.86 | 38.55 | 51.5% | 37.29 | 43.99 | 49.84 | 13.7% |
| Shares | 275.0M | 136.0M | 130.4M | 125.0M | 120.0M | -56.4% | 116.6M | — | — | — |
| Debt | 7.5B | 7.3B | 7.4B | 7.4B | 8.6B | 3.4% | 11.8B | — | — | — |
| Equity | -2.3B | -1.9B | -2.0B | -2.1B | -2.2B | — | — | — | — | — |
| Op CF | 4.4B | 5.2B | 4.3B | 6.1B | 6.2B | 8.5% | 6.9B | — | — | — |
| Inv CF | -89.0M | -542.0M | -1.1B | -733.0M | -3.4B | — | — | — | — | — |
| Fin CF | -6.3B | -4.4B | -3.3B | -4.0B | -4.6B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MCK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MCK | McKesson Corporation(you) | $104.2B | 75 | Buy |
| COR | Cencora, Inc. | $61.5B | 65 | Hold |
| CAH | Cardinal Health, Inc. | $54.6B | 91 | Strong Buy |
| SIG.AX | Sigma Healthcare Limited | $22.1B | 51 | Hold |
| HSIC | Henry Schein, Inc. | $10.0B | 84 | Strong Buy |
| 601607.SS | Shanghai Pharmaceuticals Holding Co., Ltd | $9.0B | 83 | Strong Buy |
| 1099.HK | Sinopharm Group Co. Ltd. | $6.3B | 88 | Strong Buy |
| 600998.SS | Jointown Pharmaceutical Group Co., Ltd | $3.7B | 70 | Buy |
| ASKER.ST | Asker Healthcare Group AB (publ) | $3.1B | 72 | Buy |
| GALE.SW | Galenica AG | $5.2B | 60 | Hold |
Peer medians: ROE 2.0% · P/E 24.0x · Gross margin 52.2%